FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
28 letters match. Newest first.
-
DrugsSanrace Biotechnology Co., Ltd.
FDA warns Sanrace Biotechnology over CGMP failures in OTC drugs, including missing identity tests and no process validation.
High risk -
AnimalStokes Healthcare Inc. dba Epicur Pharma
FDA warned Epicur Pharma over website claims for compounded omeprazole and buprenorphine animal drugs that are false or misleading.
High risk -
DevicesSpecialty Health Products CO, LLC
Specialty Health Products was cited for quality-system, unapproved marketing, and listing violations for its Hydro-San and Aqua Cleanse colonic irrigation devices.
High risk -
DrugsK.C. Pharmaceuticals, Inc.
FDA cited K.C. Pharmaceuticals of Pomona, CA, for sterile-drug manufacturing failures, including aseptic practice problems and failed media fills.
High risk -
DevicesLonghorn Vaccines and Diagnostics LLC
Longhorn Vaccines and Diagnostics sold its PrimeStore MTM sample transport device without required quality controls or clearance for claims beyond its approved uses.
High risk -
DrugsLiquidCapsule Manufacturing, LLC
LiquidCapsule Manufacturing failed CGMP (current good manufacturing practice) for OTC drugs, including component identity testing and process validation failures.
High risk -
DrugsFoshan Yiying Hygiene Products Co., Ltd.
Foshan Yiying, a Chinese OTC drug maker, lacked finished-product testing, stability data and process validation; FDA has blocked its imports.
High risk -
DrugsGuangxi Yulin Pharmaceutical Group Co. Ltd.
FDA warned Guangxi Yulin Pharmaceutical Group that its OTC drugs lacked release testing and had data integrity failures.
High risk -
DrugsGussyup LLC dba Private Label Grooming
FDA found Gussyup LLC, a Henderson, Nevada OTC drug maker, lacking quality oversight and ingredient identity testing; company stopped drug production.
High risk -
DrugsZhejiang Uniquality Nursing Products Technology Co., Ltd. dba ZheJiang YouQuan Care Products Technology Co., Ltd.
FDA warns Zhejiang Uniquality over inadequate OTC drug component testing and quality oversight; import alert issued.
High risk -
DrugsDiamond Chemical Co., Inc.
Diamond Chemical Co. in East Rutherford, NJ, made OTC hand sanitizers without required ingredient and finished-product testing or process validation.
High risk -
FoodFuyang Fuchunjiang Canned Food Co., Ltd.
FDA says Fuyang Fuchunjiang under-processed 230g roasted gluten pouches and lacked retort flow/temperature records.
High risk -
FoodThuan Thien Producing Trading Limited Company
FDA warns Thuan Thien that its frozen juices lack validated 5-log pathogen reduction and coconut juice treatment is inadequate.
High risk -
FoodBarsotti Juice Company, Inc.
FDA warned Barsotti Juice that its organic carrot juice safety plan does not control Clostridium botulinum.
High risk -
DrugsSaruhan Kimya Ve Temizlik Urunleri Sanayi Ticaret Anonim Sirketi Corlu Subesi
FDA found manufacturing violations at Turkish OTC drug maker, including missing identity, release, and stability testing for hand sanitizers.
High risk -
FoodSol-ti Inc.
FDA found Sol-ti's ready-to-drink juices lacked validated pathogen controls and required safety monitoring.
High risk -
FoodJuicer Connections, Inc.
FDA says Juicer Connections shipped juice with juice-safety-plan and sanitation failures and mislabeled watermelon and carrot juices.
High risk -
DrugsZermat International S.A. de C.V.
FDA warns Zermat International about current good manufacturing practice violations for OTC drugs, including releasing out-of-specification lots without investigation.
High risk -
FoodOregon’s Wild Harvest, Inc.
FDA warned Oregon's Wild Harvest after a September 2021 inspection found dietary supplement manufacturing violations: unproven identity and strength tests and foreign material in ingredients.
High risk -
DrugsDSP Skin Care LLC
FDA cites DSP Skin Care for manufacturing failures and unapproved, misbranded Hongosan antifungal drugs.
High risk -
FoodRuss Davis Wholesale Inc
FDA warns Russ Davis Wholesale of juice safety-plan failures and allergen cross-contact at Eagan, MN ready-to-eat food facility.
High risk -
FoodYakamoz Sirke Ferm Urunleri Gida Tas San Ve Tic Ltd STI
FDA says Turkish juice maker Yakamoz lacked a validated HACCP (juice safety) plan for lemon and lime juice.
High risk -
DrugsHealth Plus Inc.
FDA warned Health Plus Inc. over manufacturing quality failures in its Super Colon Cleanse laxative made in Chino, California.
High risk -
DevicesDSAART, LLC. dba Alpha Aesthetics
FDA warned Alpha Aesthetics after inspection found unvalidated sterilization and manufacturing, poor complaint handling, and missed injury reports for silicone implants.
High risk -
DevicesCellEra LLC
CellEra LLC's sterile silver wound dressings have repeated quality-system violations and uncleared labeling claims, FDA says.
High risk -
DevicesMagnolia Medical Technologies, Inc.
Magnolia Medical Technologies received an FDA warning letter for current good manufacturing practice violations affecting its Steripath Gen 2 blood collection system.
Medium -
DrugsBiotek India
Biotek India, an OTC drug maker, lacked active-ingredient testing and sold an unapproved 99% isopropyl rubbing alcohol.
High risk -
DrugsDibar Nutricional S. de R.L. de C.V.
Dibar Nutricional's OTC drugs drew FDA CGMP violations and an import alert over missing testing.
High risk